Lead Product(s) : Dobutamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hikma Exceeds 150 Injectable Medicines in The US with Launch of Dobutamine Injection, USP
Details : Dobutamine injection stimulates heart muscle and improves blood flow by helping the heart pump better, which is used short-term to treat cardiac decompensation due to weakened heart muscle.
Product Name : Dobutamine-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 14, 2023
Lead Product(s) : Dobutamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dobutamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dobutamine on the Cardiac Conduction System
Details : Dobutamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arrhythmias, Cardiac.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2020
Lead Product(s) : Dobutamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dobutamine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I/ Phase II
Sponsor : Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children’s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni
Deal Size : Inapplicable
Deal Type : Inapplicable
Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period
Details : Dobutamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Shock.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2017
Lead Product(s) : Dobutamine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I/ Phase II
Sponsor : Hospital Universitario La Paz | Brighton and Sussex University Hospitals NHS Trust | University of Luebeck | Servicio Vasco de Salud Osakidetza | University of Liverpool | Vest Children’s Hospital | Datteln University Witten-Herdecke | Iuliu Hatieganu Uni
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
